Win an All-Access Pass!
Become a new yearly Curie (Radium) or Roentgen (Gold) Radiopaedia Supporter during December and be in the running to win one of four 12-month All-Access Passes. Find out more.

SeHCAT

Andrew Murphy and Dr David Little et al.

SeHCAT™ (23-seleno-25-homo-tauro-cholic acid or tauroselcholic acid) is a radiopharmaceutical used in the investigation of bile salt malabsorption, which is a cause of chronic diarrhea. 

Characteristics

  • physical half-life: 118 days

Uses, dosage and timings

A capsule containing SeHCAT is ingested with water. The patient is scanned using a gamma camera 2-3 hours after ingesting the capsule. The patient is rescanned after 7 days and the percentage of retention is calculated.

More than 15% retention is normal and mitigates against a diagnosis of bile salt malabsorption. 

Imaging technology

Article information

rID: 39306
Synonyms or Alternate Spellings:
  • 23-seleno-25-homo-tauro-cholic acid

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.